Earnings · Brazil

Hypera (B3: HYPE3) reported second-quarter 2026 net profit from continuing operations of R$490.0 million (US$96.4 million), a 15.0% rise year-on-year, as wider gross margins and disciplined working-capital management offset double-digit increases in marketing and selling expenses.

Top-line expansion and margin recovery

Net revenue reached R$2.3367 billion (US$459.7 million) in the April-to-June period, an 8.5% increase over the same quarter of 2025. Gross profit grew even faster, rising 11.5% to R$1.4437 billion (US$284 million), lifting the gross margin by 1.7 percentage points to 61.8%.

The margin improvement reflects a more profitable product mix weighted toward branded generics and consumer health, categories where the company has been consolidating market share. Pharmacy sell-out data confirmed demand strength, with Hypera’s retail sales climbing 7.6% in the quarter, outpacing the market by 1.4 percentage points.

Earnings before interest, tax, depreciation and amortisation from continuing operations came to R$754.9 million (US$148.5 million), 4.1% above the year-earlier figure. The EBITDA advance was more measured than the gross-profit jump because the company raised commercial investment, with marketing expenses up 13.7% to R$410.9 million (US$80.8 million).

Profit quality and below-the-line items

Statutory net profit was R$490.2 million (US$96.4 million), virtually identical to the continuing-operations figure of R$490.0 million (US$96.4 million), indicating that there were no material discontinued items distorting the bottom line. Basic earnings per share from continuing operations reached R$0.70 (US$0.14) for the quarter, taking the first-half total to R$1.25 (US$0.25).

The company disclosed no large non-cash mark-to-market gains, tax credits or one-off asset sales that would inflate reported profit. The 15.0% year-on-year profit growth therefore represents an operationally driven improvement backed by higher volumes and wider margins.

Selling expenses rose 18.7% and general and administrative expenses climbed 33.6%, both measured against the second quarter of 2025. The increase in administrative costs reflected investments in technology platforms and one-time organisational adjustments that are expected to moderate over the second half.

Live Company IntelligenceHypera S.A — the full investor dossier

Valuation & profitability

Price & risk

$19.8852-wk high

$27.11

Revenue trend · 6y

R$7.70B

Ownership

Dividend

What Hypera does.Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina,…

Inventory destocking and channel dynamics

Hypera spent the first half of 2026 normalising inventories across its wholesale and pharmacy channels after an aggressive destocking cycle that peaked in late 2025. The 7.6% sell-out growth, which was comfortably above the company’s sell-in pace during the same quarter, confirms that trade destocking is largely complete.

With pharmacy shelves now aligned to end-consumer demand, the gap between factory sales and retail offtake should narrow further in the third quarter. That normalisation is important for foreign investors because it reduces the quarterly volatility in reported revenue that characterised the past eighteen months.

Hypera’s ability to grow sell-out above the market for another consecutive quarter reinforces the pricing power of its portfolio, which spans Buscopan generics, the Benegrip cold-and-flu franchise and the Neosaldina analgesic line. Each brand umbrella performed in line with or ahead of its therapeutic category.

Cash generation and balance-sheet resilience

Operating cash flow reached R$819.2 million (US$161.2 million), equivalent to 108.5% of EBITDA from continuing operations, a ratio that highlights strong conversion of accounting earnings into cash. After deducting capital expenditure, free cash flow stood at R$637.8 million (US$125.5 million) for the quarter.

The cash surplus allowed the board to approve interest-on-capital payments of R$185.2 million (US$36.4 million), or R$0.26 (US$0.05) per share, while still reducing gross debt. Net debt was reported at R$7.482 billion (US$1.47 billion), representing a ratio of 2.1 times EBITDA from continuing operations over the last twelve months.

That ratio is well inside the covenants of Hypera’s long-term debenture programme and provides headroom to absorb the higher interest-rate environment without curtailing dividends. With the Selic rate still restrictive, the discipline shown on net debt is likely to be viewed favourably by fixed-income investors reviewing the company’s credit profile.

Outlook and Latin American context

Hypera entered the second half of 2026 with a cleaner channel, a gross margin above 61% and an annualised free-cash-flow run rate north of R$2.5 billion (US$491.9 million), giving management scope to blend organic investment with bolt-on acquisitions in consumer health. The first-half figures underscore the recovery’s breadth: cumulative net revenue reached R$4.35448 billion (US$856.7 million) and cumulative net profit R$837.08 million (US$164.7 million).

For foreign portfolio investors, the results add to evidence that Brazil’s listed pharmaceutical sector is delivering earnings growth even as the central bank keeps the Selic at a elevated level. Hypera’s domestic demand driver—pharmacy footfall correlated with an ageing population and expanding private healthcare coverage—is largely uncorrelated with the global trade tensions that have unsettled export-oriented Brazilian industrials.

The main external risk remains a sharper-than-expected slowdown in Brazilian consumer spending if unemployment were to rise, though Hypera’s exposure to non-discretionary health categories provides a partial buffer. The company’s next trading update is expected with third-quarter figures in November.

Frequently Asked Questions

What was Hypera’s net profit in the second quarter of 2026?

Net profit from continuing operations was R$490.0 million (US$96.4 million), up 15.0% from the same period in 2025. Statutory net profit was R$490.2 million (US$96.4 million).

How much cash did Hypera generate in Q2 2026?

Operating cash flow reached R$819.2 million (US$161.2 million), representing 108.5% of EBITDA from continuing operations. Free cash flow after capex was R$637.8 million (US$125.5 million).

Did Hypera’s gross margin improve?

Yes, the gross margin expanded by 1.7 percentage points year-on-year to 61.8%, driven by a favourable product mix and higher pharmacy sell-out.

Source: Hypera (HYPE3) results for the second quarter of 2026 – Visno Invest

Source: Hypera (HYPE3): Receita sobe 8,5% e lucro avança 15% – Renova Invest

Source: Hypera central de resultados – RI Hypera

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.